Amelioration of Dextran Sodium Sulfate-Induced Colitis in Mice through Oral Administration of Palmitoylethanolamide
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- Mice with dextran sodium sulfate (DSS)-induced experimental colitis
- Dose used in the study
- Palmitoylethanolamide encapsulated in phytosomes, at a human-equivalent dose of 123 mg/kg, once or twice daily, oral
- Duration
- Not stated in the abstract
- What was measured
- Clinical signs of colitis, gross mucosal injury, and leukocyte recruitment at inflamed venules.
What the authors reported
Palmitoylethanolamide reduced clinical signs of colitis, reduced gross mucosal injury and suppressed leukocyte recruitment at inflamed venules in DSS-induced experimental colitis.
Limits of this study
A mouse model of colitis; it cannot show effect in people with ulcerative colitis. One author received funding from MITACS, and three authors are former employees of Panag Pharma Inc.
Source
PubMed 38790962 · doi:10.3390/biomedicines12051000
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.